Page last updated: 2024-10-26

pentetic acid and HbS Disease

pentetic acid has been researched along with HbS Disease in 2 studies

Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.

Research Excerpts

Excerpt	Relevance	Reference
"Group A (n = 20) had sickle cell anemia without clinical evidence of cerebrovascular disease."	1.29	Cerebral perfusion in children: detection with dynamic contrast-enhanced T2*-weighted MR images. ( Ball, WS; Dunn, RS; Kirks, DR; Majumdar, S; Massoth, RJ; Tzika, AA, 1993)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ware, RE	1
Rees, RC	1
Sarnaik, SA	1
Iyer, RV	1
Alvarez, OA	1
Casella, JF	1
Shulkin, BL	1
Shalaby-Rana, E	1
Strife, CF	1
Miller, JH	1
Lane, PA	1
Wang, WC	1
Miller, ST	1
Tzika, AA	1
Massoth, RJ	1
Ball, WS	1
Majumdar, S	1
Dunn, RS	1
Kirks, DR	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)[NCT00006400]			Phase 3	193 participants (Actual)	Interventional	2000-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in the Renal Function That Was Measured by Diethylenetriaminepentaacetic Acid (DTPA) Glomerular Filtration Rate (GFR)

DTPA GFR was originally a co-primary efficacy outcome for the study. Later in May 29, 2009, this measurement was discontinued because of statistical futility (an extremely small chance that the difference between treatment groups would be statistically significant for this outcome) and the small risk posed by the radiation exposure involved with performing the DTPA GFR test. Subjects who had missing data at baseline or 2 years measurement were excluded from the analysis (29 subjects from the hydroxurea, and 31 subjects from the placebo group excluded). (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years

Intervention	mL/min/1.73m^2 (Mean)
Hydroxyurea	22.56
Placebo	20.74

Change From Baseline in the Renal Function That Was Measured by GFR (Calculated Using New Schwartz Formula)

GFR was calculated using new Schwartz formula: 39.1× [height (cm)/serum creatinine (mg/dL)]0.516 × [1.8/cystatin C]0.294 × [30/blood urea nitrogen]0.169 × [1.099]if male × [height(m)/1.4]0.188. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years

Intervention	mL/min/1.73m^2 (Mean)
Hydroxyurea	10.57
Placebo	14.33

Change From Baseline in the Renal Function That Was Measured by Glomerular Filtration Rate (GFR) (Calculated Using Schwartz Formula)

Schwartz formula used to calculate GFR is: 0.55× height (cm)/serum creatinine (mg/dL). Where height is in cm and serum creatinine is in mg/dL. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years

Intervention	mL/min/1.73m^2 (Mean)
Hydroxyurea	28.65
Placebo	33.36

Trials

1 trial available for pentetic acid and HbS Disease

Article	Year
Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. The Journal of pediatrics, 2010, Volume: 156, Issue:1 Topics: Anemia, Sickle Cell; Creatinine; Glomerular Filtration Rate; Humans; Infant; Kidney; Pentetic Acid;	2010

Other Studies

1 other study available for pentetic acid and HbS Disease

Article	Year
Cerebral perfusion in children: detection with dynamic contrast-enhanced T2-weighted MR images. Radiology, 1993, Volume: 187, Issue:2* Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Flow Velocity; Blood Volume; Cerebrovascular Circulati	1993